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Abstract Microsatellite instability (MSI) is a feature of colorectal tumors that develops as a 
result of inactivation of the DNA mismatch repair system. It is found in about 15% of 
all colorectal cancers and is an important prognostic molecular marker when assessing 
patients with colorectal cancer. It can influence prognosis and treatment decisions in 
both the advanced and early stages. Although in early stages this marker suggests a 
favorable prognosis and presents an important argument against adjuvant treatment in 
stage II disease, in metastatic stages it no longer associated with such an optimistic 
outcome. The present trial is a prospective, single-center study which included 122 
colorectal cancer patients who were tested for MSI using immunohistochemistry. The 
trial included patients with stage II to IV colorectal cancer, treated in the Prof. Dr. 
Agrippa Ionescu Emergency Hospital, Bucharest, Romania. Follow-up data were 
collected during a 24-month period. The study attempted to determine whether 
differences exist in overall survival for MSI (microsatellite instability) vs. MSS 
(microsatellite stable) colorectal cancer and to ascertain whether sex of the patient 
influences prognosis in MSI patients, irrespective of stage or treatment. Results 
demonstrated no significant differences in survival for MSI vs MSS colorectal patients, 
and patients’ gender proved not to influence the outcome in MSI patients.   
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Highlights ✓ This study suggests that prognosis/ survival would be the same irrespective of gender in 
MSI vs. MSS colo-rectal cancer        
✓ further investigations, with impact on therapeutic strategy, are however necessary 
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Introduction 
Microsatellite instability (MSI) is a feature of 
colorectal tumors that develops as a result of 
inactivation of the DNA mismatch repair (MMR) 
system. It is found in about 15% of all colorectal 
cancers. Approximately 3% of these are a consequence 
of Lynch syndrome, and almost all Lynch syndromes 
test positively for microsatellite instability (1). 
Another 12% of colorectal cancers have 
microsatellite instability secondary to the inactivation of 
the MMR system due to hypermethylation of the 
promoter of the MLH1 gene. MSI can be considered 
another important molecular marker which provides 
clinical information useful in the care of patients with 
colorectal tumors. As MSI testing techniques are 
currently accessible in modern laboratories, several 
researchers have proposed more clinical applications for 
it (2). Colorectal cancer is the third most common 
neoplasm in the world and the fourth cause of mortality 
(3). 
Curative surgery is the primary treatment in non-
metastatic stages, followed by adjuvant chemotherapy 
when necessary. Genetic abnormalities involved in 
carcinogenesis include changes in the APC, k-ras, and 
p53 genes, and also microsatellite instability which acts 
as an important cause in the development of neoplasms 
(4). 
Microsatellite instability is characterized by the 
existence of a hypermutable phenotype produced by the 
loss of the DNA's ability to repair copy errors. Enzymes 
belonging to the mismatch repair system identify and fix 
the DNA's polymerase error during the cell replication 
process. When both alleles (from mother and father) are 
inoperative, functional enzymes cannot be produced to 
repair these defects, thus giving rise to a hypermutant 
phenotype. The mutations produced are evident in 
microsatellite loci and hence the name, microsatellite 
instability (MSI) (5). 
In addition to genetic modifications, the 
pathological changes for these types of tumors are 
clearly different from tumors that follow other 
carcinogenesis patterns: location is more frequently in 
the right colon (cecum, ascending colon, 1/3 right 
transverse colon) and the cells are poorly differentiated 
and atypical. They usually present with mucinous 
histology with rich peritumoral and intratumoral 
lymphocyte infiltration (6). 
Since the 1990s, the key element of adjuvant 
chemotherapy in colorectal cancer has been the 
fluoropirimidines, which have proven effective in 
patients with stage III colon cancer and stage II and III 
rectal cancer. Almost all adjuvant treatment regimens 
involve monotherapy or a combination of 5-fluorouracil 
with oxaliplatin - FOLFOX protocol (7).  
Microsatellite instability first proved its utility as a 
prognostic factor for the early stages of cancer. A meta-
analysis performed on 7642 cases identified the 
beneficial prognostic role of MSI status compared to 
patients with MSS for stage II colorectal cancer (CRC) 
(8). 
Our study attempted to determine whether MSI 
colorectal cancer is more frequent in male or female 
patients, whether sex of the patient has an impact on 
survival of MSI patients, and whether the survival of 
MSI vs. MSS patients is different irrespective of stage 
or consequent treatment. 
 
Materials and methods 
This trial was a prospective study that included 122 
patients with colorectal cancer who were operated upon 
or biopsied in the General Surgery Department of the 
Emergency Clinical Hospital, Prof. Dr. Agrippa 
Ionescu, Bucharest, Romania. The inclusion period 
lasted for 2 years (January 1, 2013 to January 1, 2015). 
Informed consent for participation was obtained from 
patients or their relatives as appropriate.  
Inclusion in the study occurred only if sufficient 
biological material was available for MSI testing 
through immunohistochemistry. Staging information 
was reported according to the standard method of 
colorectal cancer classification (TNM). Other data 
collected included the degree of cell differentiation, age, 
and gender, and these were obtained by reviewing 
observation sheets, operator protocols, and 
histopathological reports. Follow-up data sources 
included the national health electronic archives (SIUI 
system), direct interviews with patients or their 
physicians, clinical observation sheets, and death 
reports.  
The technique used to identify microsatellite 
instability was immunohistochemistry (IHC). Tumors 
with high microsatellite instability (MSI-H, classified 
only if at least 30% of the markers were positive) and 
with low microsatellite instability (MSI-L if at least one 
marker tested positively in tumor tissue) were tested for 
the presence of 4 immunohistochemical markers (by the 
use of antibodies): MLH1, PMS2, MSH2, MSH6.  
 
Statistical analysis 
Statistical analysis was performed using GraphPad 
6 Prism and MedCalc 14. 
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Results 
The patient characteristics are presented below. 
 
Table 1. Patient characteristics 
18.6% of the cases tested positive for MSI, of which 
5.6% were stage IV. The stage with the highest 
positivity for MSI was stage 3 (8.9%). Table 1 contains 
the biological characteristics of the investigated patients 
in which the majority were observed; the patients with 
microsatellite instability were more likely male, with a 
more frequent location at the level of the cecum and with 
an average degree of differentiation. 
Median survival was 34 months for MSI patients 
and 27 months for MSS patients (p=0.396). As the 
Kaplan Meyer curve (Figure 1) for these two groups 
shows, the difference in survival was not significant. 
Thus, in the first 35 months, survival appears the same, 
although after this interval MSS patients appear to have 
lower survival. At 39 months, survival of MSS patients 
is 33.3% and MSI is 28%; in contrast, at 48 months 
twice the number of patients with MSI have survived. 
 
 
 
Figure 1. Kaplan-Meier curve for MSI vs. MSS 
patients 
To determine whether sex has an impact on 
survival, we first analysed median survival: 35 months 
for women with MSI, 26 months for women with MSS; 
26 months for men with MSI, and 28 months for men 
with MSS. Figures 2 and 3 illustate survival proportions 
for each sex group. However, the Kaplan Meyer curve 
for both showed no significant differences (p=0.99) in 
survival rates. 
 
 
Figure 2. Kaplan-Meier curve for MSI vs. MSS in 
men 
 
Figure 3. Kaplan-Meier curve for MSI vs. MSS in 
women  
 
 
MS status MSI MSS 
Nr. 23 100 
Sex 
Men 8 59 
Women 15 41 
Median Age 69 65,77 
Tumor site 
Cecum 4 10 
Ascendent 5 12 
Transvers 2 5 
Descendent  3 
Sigmoid 1 24 
Rectum  37 
Cellular differentiation grade 
High 5 15 
Medium 6 29 
Low 1 9 
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Figure 4. Kaplan-Meier curve for men vs. women 
MSI patients 
 
Discussion 
MSI testing  
The current "gold standard" for DNA evaluation of 
mismatch repair mutations is PCR (polymerase chain 
reaction) (9). The tissue to be analyzed is extracted from 
both tumor tissue and normal tissue, and the DNA from 
the chromosome microsatellite—more precisely some 
of the loci from the arms of the chromosomes—is 
amplified by the polymerase, the DNA fragments are 
separated by size, and they are compared to the 
nucleotide pairs of the normal and tumor tissues. 
Microsatellite instability present in 2 of the 5 markers 
tested (30% of the markers tested) defines the tumor as 
MSI-H. The procedure is laborious, costly, and time-
consuming. The time interval from diagnosis to surgery 
is generally insufficient to obtain the  test results, results 
that could influence the course of intervention. 
For the above-mentioned considerations in our 
clinic, identification of MSI markers is achieved through 
IHC. In interpreting the results, the sensitivity 
parameters of the technique should be taken into 
account. Sensitivity is: 80-91% for MLH1 or MSH2 
mutations while the specificity is 90%. For MSH6 or 
PMS2 mutations, the sensitivity is 55-77% while the 
specificity is 90%. The global IHC sensitivity of the 
MMR gene is 83% and the specificity is 89% (10) . 
 The age of patients testing positive for 
microsatellite instability in the study group was high, 
with a median of 69 years (range = 41-90), data 
consistent with reports by Yiu et.al and Yearsley et al. 
(11). 
 This presence of MSI-H at an advanced age is due 
most likely to sporadic/spontaneous rather than 
inherited genetic changes. In this category of patients 
with colorectal cancer (CRC), the incidence of MSI-H is 
7-15% (>30 years), data confirmed in our study which 
placed the incidence at 9% (the majority of patients 
being above 60 years old) and within the norms in the 
literature. In patients under 30 with colorectal cancer, 
the incidence of MSI-H is above 50%, most likely 
denoting an inherited component rather than sporadic 
mutations (12-16). Patient age is the most important 
factor in establishing the type of deficiency. Even in the 
hereditary setting, MMR deficiency does not guarantee 
CRC. In patients with Lynch syndrome, each mutation 
is associated with a different incidence. The 
development of CRC by the age of 70 for these patients 
is as follows: 48-77% for MSH2, 41-79% for MLH1, 
12-50% for MSH6 and 15-20% for PMS 2 (17). MMR 
inactivation has some differences in the sporadic 
mutation setting, the most important being BRAF 
hotspot activation. Positive testing for BRAF V600E 
mutation certifies the sporadic character of MSI in a 
patient.  
This mutation was, unfortunately, unavailable for 
testing in the present group of patients, as it would have 
provided beneficial information, especially for the 
younger group of patients and would have made family 
genetic counseling easier (18). If MMR fails to 
recognize and correct errors (insertions, deletions, 
misincorporations) generated by the DNA polymerase, 
a high number of peptides with wrong c-terminal 
aminoacids results. These peptides are intensely 
immunogenic and are considered neoantigens. Their 
presence leads to high intratumoral T lymphocyte 
infiltration (19, 20).  Our study reports similar survival 
in the MSI vs. MSS group, which is consistent with 
reports in the literature (21).  
 The molecular profile of a tumor will very likely 
determine the patient's subsequent progression and 
survival (22). This is particularly important in cases of 
locally advanced colorectal tumors (Stage II and Stage 
III) where patients can be cured by surgery, and adjuvant 
therapy has a lower impact (23). The identification of 
clearly visible tumor markers that can influence the 
patient's incidence in a certain risk category is very 
useful. However, when adjuvant tratment containing 
fluoropyrimidines and oxaliplatin is necessitated, long-
term toxicity becomes the main issue. The possibility of 
targeting cancer cells with these drugs by using 
liposomes has been recently studied, although the 
efficacy of this method of administering chemotherapy 
on toxicity is still a matter of debate (24). Several studies 
have addressed the role microsatellite instability plays in 
colorectal cancer patients (25-27). Although many 
studies have reported good results in patients diagnosed 
with microsatellite instability, estimating the prognostic 
value of this molecular marker represents an extensive 
variation (28). 
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Why MSI is not a positive prognosis factor in the 
long run is controversial. The high intratumoral 
lymphocyte infiltration may be interpreted as a 
favorable prognostic factor, at least in the early stages of 
CRC. Some arguments for efficient immune response in 
the early stages include: the high levels of co-
stimulatory molecules necessary in the T lymphocyte 
activation, which also attracts CD4+ lymphocytes at the 
setting, and low levels of regulatory lymphocytes which 
usually inhibit the activity of cytotoxic LT. 
Nevertheless, MSI tumors can undergo an 
immunoediting processes at some point in their 
evolution. After the initial immune response, some of 
the neoantigens fail to be recognized as non-self. On the 
other hand, MSS tumors which evolve in a less 
immunogenic environment are more sensitive to a late 
immune attack (29). 
 Other immune-related factors can predict survival 
in CRC, independent of MMR status. One of the most 
cited is the lymphocyte tumor infiltration percentage. In 
MSS CRC, for example, the presence of high levels of 
CD8+TL is a factor with substantial impact on survival 
(30).  
CRC immunogenicity can also be related to the 
presence of HLA class I antigens, that leads to LT 
activation. HLA class I antigens are seldom found on the 
surface of MSI CRC cells, making them invulnerable to 
natural killer lymphocyte activity (31). 
The link between MSI and CRC immunogenicity 
can be exploited for therapeutic purposes. The most 
studied therapeutic option is represented by the immune 
checkpoint inhibitors. Pembrolizumab, an IgG4 
monoclonal antibody, is well known for its efficacy in 
treating malignant melanoma and non-small cell lung 
cancer. Its mechanism of action consists of blocking PD-
1and thus preventing the interaction with PDL-1 and 
PDL-2 (32). 
In 2015, pembrolizumab made medical history 
when it became the first FDA approved oncology drug, 
not targeted to a specific cancer site, but rather to any 
tumor harboring MSI (33). Focus on pembrolizumab 
was inevitable in CRC. One of the first phase 2 clinical 
trials that certified the efficacy of pembrolizumab in 
MSI CRC enrolled 41 patients, of which 21 were CRC-
MMR proficient, 11 were CRC-MMR deficient, and 9 
had other primary sites with MMR deficiency. All 
patients received 10 mg/kg pembrolizumab every 2 
weeks. Two endpoints were studied: the immune related 
response rate, which was superior in the other-than CRC 
histology subgroup (71%), whereas the CRC MMR 
deficient group had a response rate of 41%. None of the 
MMR proficient CRC patients responded. The second 
end-point was the 20 week immune related progression 
free survival (PFS), which clearly favored the CRC 
MMR deficient subgroup. This trial demonstrated that 
MSI is a valuable factor in influencing CRC response to 
immune-check point inhibitors (34). 
Nivolumab, another PD-1 targeting monoclonal 
antibody, was also studied in this setting. One phase 2 
trial compared nivolumab monotherapy with a 
nivolumab/ipilimumab combination in MMR deficient 
and MMR proficient metastatic CRC patients. In the 
MMR deficient group, PFS was 5.3 months for 
monotherapy but was not yet reached for the 
combination. However, MMR proficient patients had 
PFS of just 1.4 months on monotherapy (35). 
Therefore, MSI in the CRC metastatic setting is also 
an important factor in the therapeutic decision, enabling 
the choice of immunotherapy as the second or third line 
of treatment. Other therapeutic options that may have 
immunogenic potential consist of neoantigen vaccines, 
developed by analyzing the tumor genome and 
predicting which neopeptides encoded by mutant genes 
have most immunogenic potential. These epitopes can 
then be used to develop autologus T cell transplants, 
gene-modified cell therapies, or other vaccines (36). 
 
Conclusions 
Our study demonstrates that survival is the same 
irrespective of gender in MSI vs. MSS colo-rectal 
cancer. In addition, no notable differences in survival 
were found between stage IV MSI vs MSS patients, but 
a superior survival in MSS patients after 36 months 
should be taken into consideration. Other recent studies 
confirm our findings, but further research on gender 
differences is needed. 
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